TY - JOUR
T1 - A serum metabolomics-based profile in low bone mineral density postmenopausal women
AU - Miyamoto, Takeshi
AU - Hirayama, Akiyoshi
AU - Sato, Yuiko
AU - Koboyashi, Tami
AU - Katsuyama, Eri
AU - Kanagawa, Hiroya
AU - Miyamoto, Hiroya
AU - Mori, Tomoaki
AU - Yoshida, Shigeyuki
AU - Fujie, Atsuhiro
AU - Morita, Mayu
AU - Watanabe, Ryuichi
AU - Tando, Toshimi
AU - Miyamoto, Kana
AU - Tsuji, Takashi
AU - Funayama, Atsushi
AU - Nakamura, Masaya
AU - Matsumoto, Morio
AU - Soga, Tomoyoshi
AU - Tomita, Masaru
AU - Toyama, Yoshiaki
N1 - Funding Information:
We thank S. Ikeda, F. Shoji and N. Yamaguchi for technical support. T. Miyamoto was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a grant from the Japan Agency for Medical Research and Development. Y. Sato and K. Miyamoto were supported by a grant-in-aid for Scientific Research in Japan. This study was also supported in part by a research grant from the Eli Lilly Scientific foundation .
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Osteoporosis is characterized as a metabolic disorder of bone tissue, and various metabolic markers are now available to support its diagnosis and evaluate treatment effects. Substances produced as end products of metabolomic activities are the correlated factors to the biological or metabolic status, and thus, metabolites are considered highly sensitive markers of particular pathological states, including osteoporosis. Here we undertook comprehensive serum metabolomics analysis in postmenopausal women with or without low bone mineral density (low BMD vs controls) for the first time using capillary electrophoresis/mass spectrometry. Among the metabolites tested, 57 were detected in sera. Levels of hydroxyproline, Gly-Gly and cystine, differed significantly between groups, with Gly-Gly and cystine significantly lower in the low BMD group and hydroxyproline, a reported marker of osteoporosis, significantly higher. Levels of TRACP5b, a bone resorption marker, were significantly higher in the low BMD group, supporting the study's validity. Taken together, our findings represent novel metabolomic profiling in low BMD in postmenopausal women.
AB - Osteoporosis is characterized as a metabolic disorder of bone tissue, and various metabolic markers are now available to support its diagnosis and evaluate treatment effects. Substances produced as end products of metabolomic activities are the correlated factors to the biological or metabolic status, and thus, metabolites are considered highly sensitive markers of particular pathological states, including osteoporosis. Here we undertook comprehensive serum metabolomics analysis in postmenopausal women with or without low bone mineral density (low BMD vs controls) for the first time using capillary electrophoresis/mass spectrometry. Among the metabolites tested, 57 were detected in sera. Levels of hydroxyproline, Gly-Gly and cystine, differed significantly between groups, with Gly-Gly and cystine significantly lower in the low BMD group and hydroxyproline, a reported marker of osteoporosis, significantly higher. Levels of TRACP5b, a bone resorption marker, were significantly higher in the low BMD group, supporting the study's validity. Taken together, our findings represent novel metabolomic profiling in low BMD in postmenopausal women.
KW - Cystine
KW - Gly-Gly
KW - Low bone mineral density
KW - Metabolite
KW - Metabolomics
KW - Postmenopausal women
UR - http://www.scopus.com/inward/record.url?scp=84994807449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994807449&partnerID=8YFLogxK
U2 - 10.1016/j.bone.2016.10.027
DO - 10.1016/j.bone.2016.10.027
M3 - Article
C2 - 27989648
AN - SCOPUS:84994807449
SN - 8756-3282
VL - 95
SP - 1
EP - 4
JO - Bone
JF - Bone
ER -
